Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

Q1 2025 Earnings Call Transcript May 12, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

The GMP master cell bank of HCW9206 and its manufacturing process has been established, and its drug master file as an ex vivo reagent has also been filed with the US Food and Drug Administration. The ...

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

Patient enrollment and randomization for the trial was initiated in early 2025 and is expected to be completed in 2026. In ...

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionised cancer treatment, especially for aggressive and ...

After treatment with CAR-T cells - immune cells engineered to attack cancer - patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating.

Once prostate cancer no longer responds to hormonal therapy, the cancer is called castration-resistant. Find out which ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...